<SEC-DOCUMENT>0001193125-11-309212.txt : 20111114
<SEC-HEADER>0001193125-11-309212.hdr.sgml : 20111111
<ACCEPTANCE-DATETIME>20111114084454
ACCESSION NUMBER:		0001193125-11-309212
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20111111
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20111114
DATE AS OF CHANGE:		20111114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		111198019

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d255699d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): November&nbsp;14, 2011 (November 11, 2011) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;8 &#151; Other Events </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;11, 2011, ARCA biopharma, Inc. announced
that two Gencaro (bucindolol hydrochloride) abstracts have been selected for oral presentation at the American Heart Association&#146;s Scientific Sessions 2011, being held November&nbsp;12-16, 2011 in Orlando, Florida and that ARCA&#146;s CEO,
Dr.&nbsp;Michael Bristow, has been selected as one of the invited speakers on the conference session, &#147;Clinical Implications of Cardiovascular Pharmacogenomics.&#148; The press release is furnished as Exhibit&nbsp;99.1 hereto, the contents of
which are incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Gencaro&#153; Atrial Fibrillation and Pharmacogenetics Presentations At The American Heart Association Scientific Sessions 2011,&#148; dated November 11,
2011.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: November&nbsp;14, 2011 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael R. Bristow</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael R. Bristow, M.D., Ph.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEX TO EXHIBITS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Gencaro&#153; Atrial Fibrillation and Pharmacogenetics Presentations At The American Heart Association Scientific Sessions 2011,&#148; dated November 11,
2011.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d255699dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g255699g41c66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">derek.cole@arcabiopharma.com
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GENCARO<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> ATRIAL FIBRILLATION AND PHARMACOGENETICS </FONT></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRESENTATIONS AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>SESSIONS 2011 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA CEO
Dr.&nbsp;Bristow Selected as one of Invited Speakers on Session Discussing Clinical </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Implications of Cardiovascular
Pharmacogenomics </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gencaro Potentially the First Genetically-Targeted Treatment for Prevention of Atrial </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fibrillation </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, November&nbsp;11, 2011</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted
therapies for atrial fibrillation and other cardiovascular diseases, announced today that two Gencaro (bucindolol hydrochloride) abstracts have been selected for oral presentation at the American Heart Association&#146;s Scientific Sessions 2011,
being held November&nbsp;12-16, 2011 in Orlando, Florida. The abstracts present atrial fibrillation data from the pivotal Phase 3 BEST trial of Gencaro. In addition, ARCA&#146;s CEO, Dr.&nbsp;Michael Bristow, has been selected as one of the invited
speakers for the conference session, &#147;Clinical Implications of Cardiovascular Pharmacogenomics.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Bristow will present
&#147;Genetic Guided Drug Development in Heart Failure&#148; during the session &#147;Clinical Implications of Cardiovascular Pharmacogenomics,&#148; Sunday, November&nbsp;13, 2011, 8:00 &#150; 11:00 am Eastern. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Ryan Aleong, Assistant Professor of Medicine, Cardiology, Director of Implanted Cardiac Device Clinic, University of Colorado Hospital, and
Interim Director of Arrhythmia Services at Denver Health Medical Center, is scheduled to present both Gencaro abstracts: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Prevention of Atrial Fibrillation by Bucindolol is Completely Dependent on the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism.&#148;
(Expanded Panel Discussion &#150; EPD.400.03 &#150; Atrial Fibrillation: Novel Insights into Mechanisms; Wednesday, November&nbsp;16, 2011, from 9:00 a.m. to 11:45 a.m. Eastern). </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Is New Onset Atrial Fibrillation a Surrogate Marker for Heart Failure Progression?&#148; (Abstract Oral Session &#150; AOS.516.01 &#150;
Ventricular Function/Hemodynamics and Biomarkers; Wednesday, November&nbsp;16, 2011, from 2:00 p.m. to 5:10 p.m. Eastern). </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Atrial Fibrillation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Atrial fibrillation is a disorder in which the normally regular and coordinated contraction pattern of the heart&#146;s two small upper chambers (the atria) becomes irregular and uncoordinated. The
irregular contraction pattern associated with atrial fibrillation causes blood to pool in the atria, predisposing the formation of clots. These clots may travel from the heart and become lodged in the arteries leading to the brain and other organs,
thereby blocking necessary blood flow and potentially resulting in stroke. In addition, in patients with heart failure with reduced left ventricular ejection fraction (HFREF), new onset atrial fibrillation may also contribute to worsening heart
failure and increased risk of death. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Studies estimate atrial fibrillation affected between 2 and 3&nbsp;million Americans in 2005. Those same
studies estimate the prevalence of atrial fibrillation will likely increase to between 3.8&nbsp;million and 4.8&nbsp;million by 2025. Industry estimates expect the atrial fibrillation drug market in developed countries to increase more than
eight-fold, from $843 million in 2009 to $6.8 billion in 2019. The Company believes there is an unmet medical need for new atrial fibrillation treatments that have fewer side effects than currently available therapies and are more effective,
particularly in patients with HFREF, where most of the approved atrial fibrillation drugs are contra-indicated or have warnings in their prescribing information. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Gencaro Atrial Fibrillation Clinical Trial </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company plans to conduct a multi-center,
randomized, double-blind clinical trial of Gencaro in symptomatic persistent atrial fibrillation patients with HFREF. The Company believes the planned study will provide important clinical data on the safety and efficacy of Gencaro in this patient
population and additional information on the potential pharmacogenetic selectivity of Gencaro. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is planning
for the atrial fibrillation trial to compare Gencaro to the beta-blocker metoprolol CR/XL in patients with the genotype (homozygous arginine position of the beta</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB
STYLE="vertical-align:baseline; position:relative; top:.4ex">1</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">389 adrenergic receptor) in which Gencaro appears to demonstrate therapeutic enhancement. Metroprolol CR/XL does not appear
to have enhancement of efficacy in patients with this genotype. The Company believes the planned trial would take approximately 2.5 years from enrollment of the first patient to completion, including data analysis. Subject to obtaining additional
financing, the Company anticipates initiating patient enrollment in the trial in the first half of 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The
Company&#146;s lead product candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
(bucindolol hydrochloride), is an investigational, pharmacologically-unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation in patients with heart failure. ARCA has identified common
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
genetic variations in the cardiovascular system that it believes interact with Gencaro&#146;s pharmacology and may predict individual patient response to Gencaro, giving it the potential to be
the first genetically-targeted treatment for the prevention of atrial fibrillation. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit
<U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release and the anticipated presentations may contain &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995.
These statements include, but are not limited to, statements regarding the adequacy of the Company&#146;s capital to support the Company&#146;s operations, the ability of genetic variations to predict individual patient response to Gencaro; the
potential for Gencaro to be the first genetically-targeted heart failure and/or atrial fibrillation prevention treatment; the projected increase in prevalence of atrial fibrillation; the projected increase in the size of the atrial fibrillation drug
market in developed countries; and, the potential for the planned atrial fibrillation clinical trial provide important data on the safety and efficacy of Gencaro in the trial population. Such statements are based on management&#146;s current
expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties
associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; the protection and market exclusivity provided by the Company&#146;s
intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s
filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2010 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking
statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g255699g41c66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g255699g41c66.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/0#<`P$1``(1`0,1`?_$`+````("`P$!`0$`````
M``````@)``<#!08*!`(!`0$``04!`0``````````````!P0%!@@)`P(0```%
M`@0%`P($!0('``````$"`P0%!@<`$1(((1,4%18Q(@E!%U$R(R1A<4(E&(&1
M,T/45I89"A$``0,#`P$%!`4&#P$``````0`"`Q$$!2$2!@<Q05$3"&%Q(A2!
ML3(C"9&AP4+2<_#14G*RD[,D-%1TI!46%QC_V@`,`P$``A$#$0`_`/>#7=P:
M<MW$A+5"Y,F54QDF;-`H*/'RY0`1302S#@43!J,.12YAGB&>MW7CI]T!XK_V
MGGERYC)"YMO;QC?<7,@`.R)E16E6ASS1C-P+B*J_<?XYD^2WGR>-94C5SCHU
M@\2?J':>Y"LXW=2*KM4D71+55KKR0%Y*KIN!+].:5!FHD4P_P$<<QKC\5/EV
M3S$EIP_@T%Q8%WW?G7L@F([B]L4#V-/N<5+D?1JTCA#KS(/;+37;&"WZ*N!_
M,ON0W0U2OD(4-$E`0`<^\O!'C_`&'IB4<'ZY^N.8:'OX/AX&G^5D+@G7W6JH
MY>EN%BT_Y"8G]TW]M?6;<Q5(`(^$Q/IF`=X>AG_+./\`KC*)O61UHBC+QQ##
MD@5I\]<Z_P"V5..F>&)I\]-_5L_;6J<;JZF;#[Z$BQ#+/,LR\'_3+H/7$8<E
M_$-ZU\8WOO.`XQ]NW]9F0N#I[OE5<(>DN'GT;D9J_NF_MKIZ*W604P_2CZMB
M/&^H4!-*20<F>1R0F$`+U@J)(KHE$1XGTB4H!QQD71S\3_AW+,Y'@.K&(/''
M3R!C+J*8W%JPDT`G+F1RQBIU?M+6BM5;,[TAO[*W-SAI_FMHJ6%NUY_FT)!]
MU:E%DFHFLF15(Y5$U"@<AR"!BG*8,RF*8.`@(8ZG03PW4++FV>V2W>T.:YI!
M:X'4$$:$$=A4/.:YCBQX(<#0@K]X]5\J8(N$N1<JC+2TC)5Q7LRC!4Y%`3JG
MJQ3J&,JKJY+=N@F!E7#E82CH3*`F-EPP1=-!S<54D/&S\&^0DH>79H/XU^V-
MK;NV;D@*(KHG_J(H0<PP1;7!%RM95O2=O8-:I:UG6%.0+=5-%>4DCG3:)*J@
M<4R*'(0XE$X)C],N&"*E6F\;:T^64;M;[VW571`151\B:D42`HY&!0BF@2&`
M1]!XX(L9-Y>UA591NC?:WBZZ.8*I-YM-P=/+U$Y4"*"4`_'TP1=+2NYK;Y6[
M[ME*7BM_-R',!'HVM1L"N.:.>27+742-S!RX%]1P17D4Q3E*8I@,4P`8IBB`
ME,40S`Q1#,!`0'@."+^X(M1-U!!4TP6E:BF(R#C4"F.L^EGS9@U3*4HF-FLZ
M433S`H>F>>"(9I3>]MECW"[-E<II5+IJ91-RWHN+F:L4053,!#)*=D8.R%4U
M#EEG@BU1]^6VEFJHE.5C+4MRE@0.K55(5/3[<%/=J`'$C&(I'*02^X0$0#,/
MQP16_;?</9&[T@M$6TN92M92S9D,BYC(:1*X?MF13I)G<+MA*15-,BBQ"B(A
MP$P8(KFP13!%6=Q+PVYM2K3*-?5.PIY6KYE*"@2/#"`O'ZI#GX@4!Y39/0!3
MJFR(4QR@(YF#!%9F"*8(I@B7%NS?O%KF142*YS-$*9CW2#<RF2:*[Q])I.5B
M%^AE4VR8&'Z@4,<&OQ)H,YRGU)XKB44LCL;%QZUECCK5D<DUS=LED:.YSVQ1
MAWB&-\%LOTAB@AXK->;0)G73VD]Y#6,+0?8"XT]ZJ^FX=!3D@JH9)-0V74"0
MQP*<<@$PE``,8I?J`9C_``Q6=%^BV)QD$3I(BPOVU>6[C4]YKV_1]`5]S&3E
M!=MU([NQ$-"6Y.=NN5\*+<KAD+Z*E3+I]O<%;@8RK<'&HJ8*.0$H``Y"7+TQ
MOKQWI#:6]FZ.\;$QKHO-AF)'ENV]K0XT`+]!0ZCPU4:WO)/O`8-QVOVO90[A
M7L-.V@U]ZZ7[?Q4@>&,D^9&01ATU)8&S@IU2K-C*&613XCK<K%,`%RX9AC-/
M_,<'D3:%CX70LM09MKFDU:22UOBYP.G<K7_S]W;^:'-?O,IV5!I0TH3X`=ZJ
MFJZ0<QR9G3](C(SC4=LT$@`Y.D'`JPHCF*".7H)N)ASR]!Q!/4#I/!%;R7&0
MA9%YI.R.GQ$=QV_JM\">W6@T*RS$9QL[A%`XO#>UW<#X5[S[NSO0_5$P%J8R
MI0,0WN]@`(9Y9"``'IE_OCF#UTZ.Q8XR9?%Q>7=-.YS0*5'C3]*D_$7_`)P\
MMQJU,OV^2CV6M33*[Y8SA5!N+0BAQ$R@H(%3!,%#B(F4.`&XB/$<=K/0UG<M
MG_31QV?,2NFN8+?R&N=JXLC#=NXFI<X5-7'4K6?J-:P6G+KID#=K'.W$#LJ:
MUH.X*ZL;<+!E,$2'_DAN!6^X"9KNT-I2#)45MMI]Q7UY)!LHJHW4FR@KVZ`,
MD0`,:5B2QC@4R@`@<5C?A@BN;XD]R2-R+52EFYR1YU3VP.W[.5PH;FNJ1>E5
M29-VQ3F,90(<[,05$!X<\N>6")O6"+YW;-H_;J-7S5N\:K%TJMG:"3ANJ4?4
MJB*Q3IG*/X"`X(O.1\Q%-T;1%P[4O*:IN#IUU4$)4BDPI"1C:-"248KPP-E7
M:3,B**BR0.CY'$NHVH<Q'A@B9Y\>UMK<DVJVHGT:+IA67J*G6\M,2SF$CG<F
M_>O44C.3N'SENJZ,F82\$]>@OT`,\$5#_*1MZM:WL0\NY3]+P%)5K1LLS4++
MP4<VAS2<:Z(Y.[9.T8Y)NDZ='5;IBDJ8!4)D8`'CP(M'\1.XBO+I4G<&W=:3
M#^I6EO%*=-34O)*J.I!K'RJ4KSHMX]6$RSA%#H4P;ZS&.``;,1SP1'?NZW34
MGM1M:ZKB=2+*ST@N,51],E5!-::F5$5%"<TP9G0C&N@.>L`"!!.0/4P8(D_[
M9[<7>^2FMY>ZU_ZPFRV;IJ5!!"F(A9>-@Y>2`ZHC`P3`%1;M6<<1,0<N3`JY
M`3D+J'4(@1/KH.UUNK813:%M_1E/4G'M4"-DTX>-;MESI$``*#E[H,^>'X<3
M+*',(^HX(MO5-&4E7$8K#5C34)4T6N0Z:C*;C6DBAI4#(_+*Y24%$XA_402F
M#\<$2X[;[.'FVW>)$W"L_$/%[05S1]3PM21AW?.1H:07D8)ZW(B*Z@+KL'G3
M'Z<,E#(%2,4QAU8(FA8(L:RJ:"2JZQRIHHIG554,.12)IE$YSF$>`%*4!$<$
M7F`W^7`N!?V:J&_M-D.M82U%=(VJHJ41,9PE)3FN0=2]31YDOTSQ;AS3:1C'
M/D*9C)AQSP1.PV%;BVNX[;_34^Y>@YJ^ET&U*UF110#/%9:-;E;=X<)YB*:<
MX9NHLGGZY#^&"(T\$4P1+)W8KD)>9J0QP+E1,(<0'\`DY[B&?\N.6.,GK/CA
M/JPMY)`"\<6L`/'_`!5_V>U;-=*F./"'D?YZ7^A$LMM'S(BR6N?;(<TR91:J
MP3R4(O\`BF1$B*@%#(<O;I$<_7$]='GX^&*-GST;&$#[LV[Y@[Q%-IU/?2A5
MOY-%.]I/D.-*_$)&LI[S7ZZK<7/JE5C7+"G7!080S2.0?LV"2+ABT<JN55B*
M2?0N3&,4ZX(%+QX%T<,N.'/.?NAZN'A^4/RV)M((Y(8-KXHY!(YX^8V/.I?L
MV@ZTV:4U5/QW$MEP#LE%]Y=OD+7.)#G-H!\&X>%:_3JKBIVL*/2A1(J"0N.6
M'+.!BE$IP*.8AZ#G_'Z8V4P7*N+MQ(+BSS-NAJ/RK#+_`!.5==U;7974>Q9)
MB79R-*I3BSIO&J.EWC<LHY@W<LL^;H$0%%0KPI5D$2B*I@STAG]/3'CF<C9Y
M'C@RTDD<#Y'O:)7V[YC(UH;M(?1S0#4BM%\VEK-;Y(V;&ND#0TE@D:P-))J-
MNA/9XH*ZX>MB**\J1!]J4/\`J`DNB'+^FDJP%'W9_E`.&.=76[Y)]M.1.R<;
M75.UPT[C\0TIK3P4V<=CD--T>S0:5!U^A,&VQJ%5M!3YRCJ`5''$/0?:C_OC
M>OT-,9'Z=\4QGV1++]3%!'5`%O,+@'MH/TH@<;>J/4*V\S<E"[5K!5A=.2.@
MI+(H=EH^,7-D$Q5LFBN6'8"!?U`3452$3F`!T@''UP1+>V-[A-H%I;$.DKKW
MHIB1NI=]R^JR[1I=A,O)`\A-%-G3LHY"+.5\E$`JJ4F8B'ZILO7!$G>WE^*6
MV:[WU*LMQ5(U9:./JIY'EE6'4%/4-M9ATDHL@9)RBB)7IC-B#Q((%R#+UP1>
MS^%F(VH8F-G(=ZVD8J69MW[!\S5*NU=-7*95$ED%B")5$SE-P$/7!%L\$7F=
M^=^8+&W`L,01`!5I^M!SSR_*XIO^(?C@B)#:[O1KVQ6R:V502>TJ\M8T+2]&
M-535[2$A2+R%>1**)-,THS6E"3+)D8/SB9N;3_'Z$0\R&Z.I_EVJUIMQIJ>I
M#;S0L<Y;U:ZCJC?.)NMZ^!@<S<R425FFA&@K$)NAS;`H)5A7`3?D#!$\/:]M
M8MIM0H`:'MXBZ<K/UD7M35-*"0\S4LDB10J;EZ9,`320;\]3D(ES*B50P`(Y
MYX(D"_.774TE?&V5+O#+)P,-1K]_#@94.G6>2[B.[J)4BF`>8ET*.8F_'A]<
M$3E_C(BHB-V5V67B$"(!.4\A4,EH.4_.F)5!NK(+FT_E.JH4!$!XA@B/C!%,
M$4P13!$KCY2]UZ%@K.L;=TY+`RN=>IRO34&=%0Q'4%39"%3J*J2&3U&*:-.Z
M;)E*)1$X+CD`Z1R(JBC+K?'S';/1VK+WPI-Q&JT,$1)R3:-FT%I&J0:HKNZ@
M3_M1N0\D)9#68P#GD<0SXX(E7?%ENC2L#N@/;&HYMN:B;HNC4B_>D561B"U(
MQ5,:!J$3N2I\MD"!'"13'*41Z@,\$7KUP13!$I#>Y(F87LCS`(Y>#01C^N6D
M)6?S`!X>H>N6.$WXA><?@/5+97P)$?\`UBR!I_JK[ZEMMT4MA<\&D;W_`#TO
M]G$JRH6Y;F,632;2!8PIL@5>D2*=4I?J8#"0Z^H@#F`$$IOPQ>>D'6)UK'%'
M;W#8&O<-S]H+@#37L+M*&FS:5=\_QEEPTN?&9".QM=/XORU")%:HK=W%C#^3
MM7HM*=9**(5#W`WESZ5>%TLVX.Q,HDBQ64;#J0R,0F>8"`B.>U&<'2WJ[CVW
M'*8[B-^,C)BOF3;<@Z63[#/,^)OE.<S6)P<UNI!:7&L<Q6G(N.7%,:YF^X?K
M%M^X:QOVCMT)<`=':$^V@7ZBZ2MC#NZ>3?3\^^)/0R<DW;/'J+=DP=.SJ)L&
MSXR.HZ[/F(FYIA$HB&/7!\`Z?X&YL69+,Y.[BO+42L9*]D<;'/)$;92RI='5
MIWGX:CP7S>9?D5Y%.Z"VMXW0REA<UI<YP;0N+:]CJ'0:ZK35E>-(6?3QBJE/
M.6"?2*1#=0RD"[21$_*4:LW'.2:N>(ZB"42FS+I'UQY\TZPV=MCS;8Z0V$MN
MWRS"TU@>UM:%C'[@UW;4$:U%#VJJP_$GF??<M\^.0[@\Z2-)[:N%"1X'NUJA
M$JJLNO44-FF94YQ`2D`"$,)LQ-P*`9&-^(``8YK=9>J(NQ)'#)6X>"--*GZ-
M`IDPF#\@#3X0FU[3#F4L=2:IBG#FE6.43ETZRB5'(Y?H8HB'`0X#CKSZ#!)_
M\U81TH(<XO.O?4,U]OO6JO5H!O.+MHII0?6B2QN.HV7GSK&KT?D=^2VGK2P3
MA.6VY;.5%:AK9PDHD[AJNKU5ZB!X9VFBJ*$C#R*464C9;,PIBBKZ:L$3X0H2
MAP``"C:4``````IZ(R``#(`#]GP``P1(<^=?:U&2=CZ?W%4'3[*/G+5/SQ]7
MH0C!JQ*]HR7(15:6D`;(I$4)3:L=[,^(`Z'+!%8/P:[PVM\-OSNQ]32Y%Z_L
M<+&/C4G3A('4G;YZDLA`';$.873U:(4C52.U1U:.>D`CQP1/-P1>4;_Z)9KM
M=R=N9-9B\VFJ\'V@''2YI;US$/QP1.N^+LS::V!;=RNDT7C5[;J,1<(+$(LD
MLDHT(15%=,=9#`8HB!BC@B0%\J&RNK]C]TH?=9MZ%_`VNDZH1D$AI_G(K6IK
M4RQW+9JB9,PF1IZ51`X-AS$J/(4!0?<7,B>-\9WR,T?OBMJ5A,NHZ#OK1K-J
MA75*$.1`LL0$A3"JZ?0,83*Q;U5$QE4BZA:"<A3C[RX(J7^9K936&X^TT!=6
MTL6O-W,L\2866IB/1(:0JRD)5)HO+(,2@(*/9J,6B$1:(Y@!B++<<P#!$'?P
MD?(11L9"+[.;R31:3JN.FG3FV#^I3#&)RO5J<M_1+I1X*)8^6CC%1Z-NH!3K
M$YOU*`"1>F[!%,$2X]YF_P#IS;Q5MM+(6U0IZXVXRZM81-/PMOW,DLDW@89W
MS3OJ@J-:.*LNR$A2`#9N(`HN.LP`!2#F1,$J">B:6@Y:HYY^UC(:$8.I.3D'
MJZ;9JT9M$C+++++JF*FF0I2^HB''!$A/8DI_["=Y%Z][M7QI7]HK;K_;:P<'
M+-`5CG21'ZPIU2DV7!1%.89,(<$WI1#(RKHH_P!.")[7@M$?]G4K_P"/1'_1
MX(O*?\Z^WC[*W3M]N8H&,2A*=K55"&J((AHFPCXBM8)1!]!.`3;@DD5W4"75
M*'$N0B+8<PP1/K^.3=='[O-KM"7#4D4G=:1+!O2UQ&YET3/B59#(E8R$FY:I
MCK:MYURV4<-]0`!R".G@'`B._!$*6YK;<E>Z-92D&^;PU:PB"Z3)TY(86<LT
M-DH6,D#$`3ID(J4W*.'`@J&$>&-*?5WZ1[#U%8VWS6$GBL>H&/B>R*1X/E7$
M9^)L$Q`+@&NKY3AHPR/)!!4K=,^I,G"+A]K>L=-A9W`N:/M,<--[.XU'VAWT
M%$JF<V];B*3?+LE[9U(^!%0Q"O(1!.6C%3"&13(.VBABF#(,PX`/''(RY],'
MJ?Z=9-UJ>,Y*XCB=3?;-^8@<>XLDB)!'\*+:&TZ@=/<Q`)F9*VC+A]F0F-X]
M[7!96E";@VZ0HC:NO>7JU:"PR^DQN&1C`!@XAE_I],2%B>.^I&SA%M+Q+D0A
M&M!;/H3XGL[.Y4TV8X#([>,I8;OW@6S<TIN$=E1(K:JO3`W0(V2SA5QTHIB8
M2$XG'(`$X^GXXR"[L/47=QL9+Q'D)\J,,;_=G_9;6@[?:5219#@,3B6Y2QJY
MU3]X.T]_YESS^V^X)\=0REKJ]4%3U.>%6,8P^FH1,.>?\\1UR#@OJ8S8.WB?
M(&DGM=;25/OHKI;9_@%N!3)V`IW"0*V;6;-KS5S+-5JRC%:`ITBJ9W[F9Y?>
M%4!-^H@PBTCG4!P)"CI,H)4RB/$>.,JZ6>@/K?U)ST5SU"@?Q[C&]IFDN"/F
M2RNK8;<$G>16ADVL::;CW+'.3=9.'X.T<S#2-O\`(D$,;'7RP>XO>=*>(%2>
MY.5I>FHFCZ>B*8@T!;1,(Q1CV"(FUF(W0+I)K/D&LX^HC]1QW<X9Q'"<"XK8
M<-XW%Y.#QULR"%A-2&,%!4]Y\3WE:=93)7>8R$V3OG;KN=Y>X^TH.MT&U>]6
MX>4?,:;WC7+L3;65IE.!E:$MQ1]*]Q?O#G=`_E#5V_6&H&97S=8B8HM@1%,$
M\RJ>X<9,J!`G8/X7IO:O4,Q5FWK?#>2W\_40-4ZC47H6B*DBZB;M%5ET4)J+
ME5A([Y:C@XE."A#E$YLAXX(G74G&34+34)$U%42E6SL?&MFLM4RL<VB%9Q\D
MF!5Y(\6S45:L#.3AJ%),QBE]`'!$OG=-L6O#NG"N*3G]ZEQJ+LI7#=TQD+1T
MG;BADVQXIT)=40_JMXJM-24<`%XDTI&,/$38(@1MK\`-*V9JQC7EI=Y5^K>5
MK&%.2/J2FHFG&;Y`BADSJ(*EZ@S=ZS5,D45$%B'24TAJ*.6")I5/6`W)PUFY
MNWLCO0JJHKA/Y-NYA[SR-I*%2GH*,236(M%^-M':4#)'<&4(87"F@Y1)P+Q'
M!$MV]7P<'W)U"RK"_P#O@OI="JF+$(]M)RU*T6P:,FVH#'0B8:+%M'1C=0P`
M)BD*)S:0U&-D&1%=%AOB_O+MAAHRD[(_(1>FG:&CWYGQJ&J"WE!5A39Q5.B+
MA-DE*K$?1)%DT=`E07!,`$!`@98(FFW&MS1MVJ%J6V]PH)C4]'U=$.H2?AI%
M+F-GS)VD*2I3%`2F(<,]13%$#%$.`X(D+T'_`//E1-JZS"N[9[P[\4'43&1<
MNJ>E:9BX",E(9@LJ51*+5?(.R]V13T%`_/3%-;2`F3X!@B<%MTLK>6SR4\SN
MEN@K+<8R?`P+3QZUHJDJ:EZ>*V!P#OGRM+@@$X=_S$\S*HIBGR^&>H<B(<=U
MWQ/;0-VDP[K2J:/?T%<]T<'"ER+9O_&9YV^3S,W>3#=-)6-E54E3"<QQ2374
M,.9E1X9$5?6]V5[^+%MFD!:[Y$7==4@R0Z9A%;@+/Q=;/8IJGP;M&TQ&3S"7
M>IID'(5'#DR@Y`/KGF1=;4^V'Y$KE,7$+5GR!0=MXU8@)F?6/L!"PU0'()#@
MJ3N%55+-].*F8!J3]P!Q#++B15)MY^%:R=DK[TSN0J>\%X;S77I:=4J=E.5Q
M)LP2>5`=-9().52*1XY?*$(Y5R*98``3YX(K4W/?'K=S=4>N*?KG?-=V`M+5
MDL\=,[3491%&P4)&PCA94[>GI6926--U.U9(G*0#KJ)`IIU'((B&DBX';/\`
M%G<3:(T;T_8[?)=B!H52;";FJ$F+=T)4$%*+'5,J\Z<SQ4CV(</A.(**HJ#G
MGQ*(@&1$X!P111!9-%86ZRB*A$EP(504%#D,5-8$S"!5!3,(&TCP'++!$G?<
MC\5]S=W,8:F;^[[;K530K6?;U)"4-#6SH&F*?BY1FD];,GRQ62Z[V2?,VK]5
M--514`*50_M]W`BJBR?PBR.VB6D*AV^;Z[^6MG9-`B+Y:+INDI"'DBIF**03
M-.22RT3*@D`"!!4("A`,(%.`"8!(FT_;6[_V3^WOW_DONCVSHOO?X!3G<^JT
M:>Y^%]9V#J?KIYFC/Z8(K[P13!%,$4P13!%,$4P153?&OXZUUIZZKJ2FQIY"
MGJ?D'R<J1FVD5V[E)`YF_2QSM5%"0=&.'L1,8-8X(A7V27*J^IJ-;5-?"ZT9
M*W`NHX-,T?1#J4AF+B-I!L)@BSL*=0,F\9NWQW9^<F<#'-H)EGE@B/"3DH^(
M8N9&4D&44P:I&5<2$BY09LFI"@(BJX<N5$D$DR^HB8P!@BHZP87+=QM1SM=7
M3HFZ<).RW6T1)43&="SCH;-;4T<N2K+)O%AU)Y:1R)I'B.>"*S9^XE!4K(LX
MBI:RIF"E'^0M(^5FH]B\6((@`*@W<+D5(@(F`.88`)F/K@B[`IBG*4Y#%.0P
M`8IBB!BF`>("4P9@("&"(6WV\2R,7>V5L9*U,UB:BA(H)"3FI5VRCJ;;/3+E
M0"`[BZ<)@>;S,(BB`9@!1S'!$3[9TV>MT7;-P@[:N$RK-W+95-=NND<-1%45
MDC'353.4<P,41`0P1+)J"]%>U'O8=VZCKLA3UE[5136JKBN#EA82(2E`<*I!
M1,K,N#&55,L0ACZ3&2.<$S9`(%$<$3'Z;JFFZQBD9RDYZ)J.&7.HFC)PK]M(
MLCJI"`*I`X:J*)\U,1#441U%SXA@BV;Z081;91[)O6D<S1#-9V^<HM&R0#Z"
MHNX.FD0/YB&"+G:>KVB:M?2T92U5P%1/X)1)*9:PLHTDE(Q1;F<HCSI%500,
MIRC:0$>.D?PP1?J1KNBHB<9TS*U;3<=44@0RC*#>S4<VE7)"E*<3I,%G!')B
MB4P"`Z?<'IGD."++3=:4A62;Y6DJG@*F2C'9F,BI!2S&5(R=E$X<AR9DNL")
MS"F;3GD!M(Y9Y#@BQNJZHMC.EIAY5E.M:B,S6D.R.)F/2DRLFXI%6=*,CK@N
MD@F*Q?<8H!QX8(M,UNY:U]'S$LSN+13F+I]<&TW(HU-#J,8QP<%A31>.BNQ0
M145!NIH`3>_0.G/+!%U4!44#544UG*:F8V>AGQ.8TDXEX@_8N"\,^6X;'43,
M(9\0SS#ZX(OKD9.-B&IWTM(,8MDF(%4>2+MNR:D$V>D#N'*B211-EPS'C@BT
M5,UU1E9JRZ%)51!U(K`.B,9HL))-9((UVISN6W=G:J*$35/TY\@SXZ1P1=7@
MBF"*8(I@BF"*8(I@BF"*8(DW?(-5P7HOC:W9B-7QMO:66C?NS=2J)M^VBVWC
M;)P5K%I1CEVLW07>MS$="*!C""FHN8<,$6*U6WN@[I[B[6UC9BD'4#9?;>Y5
M>*7>DR/>]7LKDQFG*28R;P2JS]/0J3#49R4I$!,ZR3#+/!%N/E+NC2`L;?V'
M1G`2KVX3MVW50>R;E.EJ5I=V9BB]JJI(=F4RTE()`.46`E4*!BK9D-G@B+"-
M"/VU[*74K9VFIV3\#M>XGJ<@YJ)<,*EFY%!B50AI:(.!G#>4>&*`G2RS+D`9
M8(E-N).(0V;H.UC-KU[O=[K1(B"1N15%;QE.3Z0B!6Z)>I4IR.ID[WB!0;D%
M14,PS(&1$WAZ_0VS;-6XW<F7$VM;.TS6-JB21DU4)">DXR)!!<&4AS2.3/GJ
MY!T&*;6(\0P1)THN"H6G=B5:SLU$P5?[@-W3EXA;VG(U)M6%8,TY)%R6G'C$
MCH\E/1?:@D#"[<&.02G.GJ-GIP1-PH=TYV=[)85[<YVBM)VHM@W5GR)/"BD,
MHU9$)VR/<+'S6`K@P$3^HY#D&"):VVFEK.491M<WZW3U)`57>:[4(6Z\79>1
M>%=R2T/(D=&IZ3&C%SF6FY^456.1$%$5.2`'T![C9$1N[*+?R>T7:1-57=QN
M:"?+FG;GU'`,T50\8C7:0/6\,+#4)4I%HD<2+@7^O+,1RP1`E7N^>CY.SKK<
M!7\E%7%N)6SYY`VBLNR<J/;<VA82/&/D+@H%,2.E:J<):06ZH%C9H&Y"8`"F
M")@WQQ6TI2W5@"N8X%'555'(KR5P:H-&'CVDI.I)B*S>"?G32)+4Y$&74!HY
M3*"1RJ")<P'!$"E"V-I[>1O@NA5T<5R6QEEZ@4AY:7,^=N92X-9&=NT9`C*H
M]8.5H5ZK''4.5!0A6A=)$P*"@A@B<-2]K;'[=X"MIVC*3I:V$)*IA-5E(112
MQ35P,<DZ!!X\655,BB+4KQ0$\M)2BIP#!$@ZG8FW\ZI<G?O=5K*-+*0KMQ2M
MDZ+E)AV6KKV3X*N"1CFJ9!15)[)&D@2!5=,I@0=G`#)E`"&`2+C*GMVC8>U;
M.I;D,:=+N,WBRIUZ/M\Z32CZ0M=33HX2+^IEZ>*1-@M4L>G)MD6R*J(]$"JJ
M9`]XX(G<6D4MSM'V9M*B9ISRM&V_HI6K)AW+13F%EIMXL@@O(2W:7GZ\>G+/
M%`4(F8/80WIPP1*_N;O4IMS9IC>.KY.&NG>J[8!&V_MZGS'UJ+$0\Z4YFB<Z
MT7TQDG4Z;(Q07,Y!9PHJB8Y"I@4P&(F@;`K94?;+;S3\?2Y';J0DG"SZK:B>
M1:L<%25()2&D9&'57216DZ6%TLIVQQD!56YM10#/+!$;."*8(I@BF"*8(I@B
MF"*8(I@BH2Z/^,WD4-]Y?LQY1H3[-]P_#^[\C6/*Y'?_`-QTW,ST9_IZL\N.
M>"*[8SMG;F79NA[3TR7;NV=/V[I-`<CHNE_;=-HRT:/;EZ8(JNJ7[$?<*`\P
M^UWW0Y:/C/D?C'F>CF?M>S=R_NVKFY\GD^[5GHXYX(K:6Y/)4ZCE<C0;G<[1
MR>7D.OF:_9HT^N?#+!%1=NO\:?)GOVK^SOE_2_NO#/$^_P#;]9\^7VK]]V[F
M9Y\O]'/U^F"(1_E#;T(O9FC1NU+W9B[5)W(I\U5EM53M)3RSMQJ5[4C4QZEJ
MBG',?3_!;FJ-"NC<?>3@7,B*RV7^,'>4OM5]F_)NB#D^)^)A/=%I3YO2!'B+
MX&N>CF\GV:M.KCIP16]6'A?8G7G_`(OXSJ3ZWS#M78M>8\KJN]?V_5J_+KXY
M^F"*MWO^.GW%I_N/V@^Z?:X[Q;K/$O,NT9J=G[%SO[ITGY^EZ?AEJY?#/!%;
M4YV3L\EY)VOL'2+=V[UTO:>ATCS^X=;^TZ71^;F>W+UP1#P'^'W@[?3_`(_?
M;SOK/E<OP/QCR72ZZ'G:/V'>-'.T<S];+5],\$1%1O:.U,^T=M['T27;^V]+
MVKMW*#D='TO[/HN1EIT>S3Z<,$6@HK[?]L<?;GP[LW<'75^%=D[9W7F#UW4=
MB_:]PYO_`!=7ZFK\W'!%N*B\>[))>6=E\;Z4_>/(NA[)T>8:^Y=R_8=+GEGS
M?9@BX&6^QOB-.=]^U'@G4,O$N[>(>(]5H-V[QSK/[-U'+SY/3>[+/3PP18*\
M^Q7D])_<O[8>7:W7A?F?C7>]>;;JNP]Y_=:M7*SY7UTY<<L$7?U3XQX[+^9]
MD\5Z)7OOD?1=B[?PYW=.X_LND]-7-]N"*AA_Q"\2@L_L!X/WLOC^KP/QOR'-
M3+H\_P"W]USU9_\`-S]<$1)-NGZ=#H^1TG)2Z7IN7T_3Z"\GD<K]/D\O+3I]
,NG++A@BS8(I@B__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
